Sucampo Pharmaceuticals, Inc. (SCMP) Shares Bought by Ativo Capital Management LLC

Ativo Capital Management LLC lifted its holdings in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 26.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 138,032 shares of the biopharmaceutical company’s stock after purchasing an additional 29,009 shares during the period. Ativo Capital Management LLC owned 0.30% of Sucampo Pharmaceuticals worth $1,449,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in SCMP. Bank of Montreal Can grew its holdings in shares of Sucampo Pharmaceuticals by 22.9% during the first quarter. Bank of Montreal Can now owns 24,775 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 4,615 shares during the last quarter. Capstone Asset Management Co. bought a new stake in shares of Sucampo Pharmaceuticals during the first quarter worth $133,000. Louisiana State Employees Retirement System bought a new stake in shares of Sucampo Pharmaceuticals during the first quarter worth $111,000. Great West Life Assurance Co. Can grew its holdings in shares of Sucampo Pharmaceuticals by 900.8% during the first quarter. Great West Life Assurance Co. Can now owns 35,778 shares of the biopharmaceutical company’s stock worth $392,000 after purchasing an additional 32,203 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Sucampo Pharmaceuticals by 107.3% during the first quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock worth $4,044,000 after purchasing an additional 190,292 shares during the last quarter. Institutional investors own 55.44% of the company’s stock.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) traded down 1.23% during trading on Wednesday, reaching $12.00. The company had a trading volume of 66,440 shares. The firm’s market capitalization is $555.90 million. Sucampo Pharmaceuticals, Inc. has a 12-month low of $9.30 and a 12-month high of $17.55. The firm’s 50 day moving average price is $11.31 and its 200 day moving average price is $10.68.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The business had revenue of $59.90 million for the quarter, compared to analyst estimates of $56.44 million. During the same quarter in the previous year, the company posted $0.24 EPS. Sucampo Pharmaceuticals’s quarterly revenue was up 15.3% compared to the same quarter last year. Analysts anticipate that Sucampo Pharmaceuticals, Inc. will post $1.02 earnings per share for the current year.

Several analysts have recently commented on the company. BidaskClub cut Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 5th. Maxim Group set a $23.00 target price on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 2nd. TheStreet cut Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday, August 2nd. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 4th. Finally, Roth Capital set a $30.00 target price on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $17.63.

ILLEGAL ACTIVITY WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Shares Bought by Ativo Capital Management LLC” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/09/20/sucampo-pharmaceuticals-inc-scmp-shares-bought-by-ativo-capital-management-llc.html.

In related news, insider Jason Patrick Meyenburg purchased 4,000 shares of Sucampo Pharmaceuticals stock in a transaction on Wednesday, September 6th. The shares were purchased at an average price of $12.13 per share, for a total transaction of $48,520.00. Following the transaction, the insider now owns 30,228 shares of the company’s stock, valued at approximately $366,665.64. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. Insiders own 4.13% of the company’s stock.

Sucampo Pharmaceuticals Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply